Roche to initiate three studies with T-DM1 for early stage HER2-positive breast cance

[News]

ImmunoGen, Inc., a biotechnology company with a proprietary Targeted Antibody Payload (TAP) technology, today announced that Roche is implementing a "three-pronged approach" to developing trastuzumab emtansine (T-DM1) for early stage HER2-positive breast cancer, according to plans outlined by Roche at its 2012 ASCO analyst event.

More... (http://www.news-medical.net/news/20120604/Roche-to-initiate-three-studies-with-T-DM1-for-early-stage-HER2-positive-breast-cancer.aspx)